Targeting Protein Found to Improve Cancer Immunotherapy
Researchers identified a protein that helps head and neck tumors evade immune cells, potentially boosting therapy effectiveness.
Updated on Sept. 19, 2026 in Cancer
Live Poll
Should medical research prioritize new methods to overcome immune resistance in cancer patients?
Scientists have discovered that the protein SHMT2 drives tumor immune evasion in head and neck squamous cell carcinoma. This metabolic discovery suggests a new way to sensitize these cancers to standard immunotherapy.
Why it matters
By identifying how this protein creates an immunosuppressive environment, researchers have uncovered a new pathway to help the immune system better recognize and fight tumor cells. This finding could eventually improve patient responses to anti-PD-1 immunotherapy treatments.
In a preclinical study using immunocompetent mouse models, researchers demonstrated that SHMT2 deficiency significantly reduced tumor progression and increased T-cell infiltration. These preliminary findings suggest the protein helps tumors build an immunosuppressive microenvironment.
The details
SHMT2 drives one-carbon metabolism, which maintains pools of S-adenosylmethionine (SAM) that epigenetically activate the LDHA gene. This activation leads to increased lactate secretion, acting as a signaling molecule that prompts cancer-associated fibroblasts to accumulate. By blocking this SHMT2-dependent axis with a drug called SHMT-IN-2, researchers can inhibit this remodeling and allow CD4 and CD8 T cells to enter the tumor.
Timeline
September 19, 2026: Findings were published detailing the role of SHMT2 in tumor microenvironment regulation.
Health Landscape
This study builds on the limitations of current immune-checkpoint inhibitors by targeting the specific metabolic drivers that exclude T cells from the tumor. It represents a shift toward addressing the metabolic-stromal mechanisms that often prevent standard immunotherapy from working.
This is a preclinical discovery, meaning it is not yet a treatment available in clinical settings. Patients undergoing immunotherapy for head and neck cancer should discuss current standard-of-care options with their oncologist as research continues to evolve.
The takeaway
The SHMT2 protein helps tumors hide from the immune system by altering the metabolic environment. Ongoing research into these metabolic pathways may provide new targets to improve how effective immunotherapy treatments are for patients with squamous cell carcinomas.
Further reading
For broader context on how novel treatments are transforming oncology, see our Cancer section.
Source note: This article includes information reported by Nature.
Live Poll
Should medical research prioritize new methods to overcome immune resistance in cancer patients?
